Application of Hsacirc0070805 in preparation of esophageal cancer prognosis prediction product or therapeutic drug
The invention discloses an application of Hsacirc0070805 in preparation of an esophageal cancer prognosis prediction product or an esophageal cancer treatment medicine. The invention discloses that the high expression level of the circular RNA Hsacirc0070805 is obviously related to the longer total lifetime (OS) of the esophageal cancer patient for the first time, and meanwhile, the Hsacirc0070805 is an independent protective prognosis factor of the esophageal cancer patient and can be used as a prognosis prediction marker of the esophageal cancer patient. The Hsacirc0070805 nano-particles are further prepared in vitro for preclinical research, and the Hsacirc0070805 nano-particles are found to be capable of effectively inhibiting growth and pulmonary metastasis of the esophagus cancer in vivo, so that a new target spot and a new drug are provided for research and development of a new drug for the esophagus cancer, and the clinical treatment effect and prognosis of the esophagus cancer are improved..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 29. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WANG MINGHUI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-29, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
CN117305449 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000656399 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000656399 | ||
| 003 | DE-627 | ||
| 005 | 20240322142952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000656399 | ||
| 035 | |a (EPA)CN117305449 | ||
| 035 | |a (EPA)89254348 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WANG MINGHUI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of Hsacirc0070805 in preparation of esophageal cancer prognosis prediction product or therapeutic drug |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-29, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 | ||
| 520 | |a The invention discloses an application of Hsacirc0070805 in preparation of an esophageal cancer prognosis prediction product or an esophageal cancer treatment medicine. The invention discloses that the high expression level of the circular RNA Hsacirc0070805 is obviously related to the longer total lifetime (OS) of the esophageal cancer patient for the first time, and meanwhile, the Hsacirc0070805 is an independent protective prognosis factor of the esophageal cancer patient and can be used as a prognosis prediction marker of the esophageal cancer patient. The Hsacirc0070805 nano-particles are further prepared in vitro for preclinical research, and the Hsacirc0070805 nano-particles are found to be capable of effectively inhibiting growth and pulmonary metastasis of the esophagus cancer in vivo, so that a new target spot and a new drug are provided for research and development of a new drug for the esophagus cancer, and the clinical treatment effect and prognosis of the esophagus cancer are improved. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12Q: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (immunoassay g01n0033530000); compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LEI KAI |4 aut | |
| 700 | 0 | |a LIN HUAYUE |4 aut | |
| 700 | 0 | |a LIANG RUIHAO |4 aut | |
| 700 | 0 | |a LIANG JIALU |4 aut | |
| 700 | 0 | |a TAN BINGHUA |4 aut | |
| 700 | 0 | |a XU KE |4 aut | |
| 700 | 0 | |a WU DUOGUANG |4 aut | |
| 700 | 0 | |a WANG KEFENG |4 aut | |
| 700 | 0 | |a HU XUETING |4 aut | |
| 700 | 0 | |a WANG WENJIAN |4 aut | |
| 700 | 0 | |a WANG KEXI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 29. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:29 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89254348/publication/CN117305449A1?q=CN117305449 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 29 |c 12 | ||